<SEC-DOCUMENT>0000950170-23-063019.txt : 20231113
<SEC-HEADER>0000950170-23-063019.hdr.sgml : 20231113
<ACCEPTANCE-DATETIME>20231113163016
ACCESSION NUMBER:		0000950170-23-063019
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231113
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231113
DATE AS OF CHANGE:		20231113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REVELATION BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001810560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				843898466
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39603
		FILM NUMBER:		231399294

	BUSINESS ADDRESS:	
		STREET 1:		4660 LAJOLLA VILLAGE DRIVE
		STREET 2:		SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		650-800-3717

	MAIL ADDRESS:	
		STREET 1:		4660 LAJOLLA VILLAGE DRIVE
		STREET 2:		SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Petra Acquisition Inc.
		DATE OF NAME CHANGE:	20200423
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>revb-20231113.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-11-13T14:10:24.2094+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:revb="http://revbiosciences.com/20231113">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_e4b72d34-0f68-47b5-99e7-7bd7255ac2c1" name="dei:EntityCentralIndexKey" contextRef="C_f99bc82d-c3aa-4874-80c1-213e4ff83b74">0001810560</ix:nonNumeric><ix:nonNumeric id="F_2261d8c6-f0fa-463f-b20f-c95219f623b6" name="dei:AmendmentFlag" contextRef="C_f99bc82d-c3aa-4874-80c1-213e4ff83b74">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="revb-20231113.xsd"></link:schemaRef><